Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ancrod - Nordmark Arzneimittel

Drug Profile

Ancrod - Nordmark Arzneimittel

Alternative Names: NM-V; Viprinex

Latest Information Update: 03 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; Neurobiological Technologies; Nordmark Arzneimittel
  • Class Antithrombotics; Serine endopeptidases; Venoms
  • Mechanism of Action Fibrinogen inhibitors; Plasminogen activator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Sensorineural hearing loss
  • Market Withdrawal Heparin-induced thrombocytopenia and thrombosis syndrome; Peripheral vascular disorders; Thromboembolism
  • Discontinued Stroke

Most Recent Events

  • 30 Oct 2018 Nordmark Arzneimittel completes a phase I/II trial in Sensorineural hearing loss in Czech Republic, Germany (SC) (IV) (NCT01621256)
  • 24 Jun 2018 Biomarkers information updated
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top